[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100219654":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":11,"centralContacts":10,"locations":16,"responsibleParty":27,"collaborators":10,"id":30,"slug":31,"hasResults":32,"nctId":33,"briefTitle":34,"officialTitle":10,"acronym":35,"eligibilityCriteria":36,"healthyVolunteers":32,"sex":37,"minAge":10,"maxAge":10,"enrollmentInfo":38,"targetDuration":10,"studyType":41,"phases":10,"briefSummary":42,"conditions":43,"keywords":45,"overallStatus":48,"whyStopped":10,"lastUpdateSubmitDate":49,"lastUpdatePostDateStruct":50,"startDateStruct":52,"completionDateStruct":10,"leadSponsor":54,"locationsCount":55},{"fullName":5,"class":6},"Yonsei University","OTHER",[8],{"label":9,"type":10,"description":10,"interventionNames":10},"gastric adenocarcinoma",null,[12],{"name":13,"affiliation":14,"role":15},"Jae Yong Cho, M.D.,Ph.D.","Gangnam Severance Hospital, Yonsei University","PRINCIPAL_INVESTIGATOR",[17],{"facility":18,"status":10,"city":19,"state":10,"zip":10,"country":20,"countryCode":10,"cosmosGeoPoint":21,"geoPoint":26,"contacts":10},"Gangnam Severance Hospital","Seoul","South Korea",{"type":22,"coordinates":23},"Point",[24,25],126.9784,37.566,{"lat":25,"lon":24},{"type":15,"investigatorFullName":28,"investigatorTitle":29,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Jae Yong Cho","Chief of division of medical oncology, Gangnam Severance Hospital","100219654","investigation-of-the-proportion-of-human-epidermal-growth-factor-receptor-2-protein-overexpression-of-gastric-adenocarcinoma-and-prognostic-effect-of-her2-and-analysis-of-practice-pattern-of-herceptin-use-in-stage-iv-gastric-cancer-100219654",false,"NCT02136836","Investigation of the Proportion of Human Epidermal Growth Factor Receptor 2 Protein Overexpression of Gastric Adenocarcinoma and Prognostic Effect of HER2, and Analysis of Practice Pattern of Herceptin Use in Stage IV Gastric Cancer","HER2","Inclusion Criteria:\n\n1. Histologically confirmed gastric adenocarcinoma\n2. Patients were diagnosed during 2006-2013\n3. HER2 expression status was evaluated in primary gastric cancer or metastatic lesion.\n\nExclusion Criteria:\n\n* Patients with second primary cancer within 5 years","ALL",{"count":39,"type":40},860,"ESTIMATED","OBSERVATIONAL","The objective of this study is to investigate the proportion of HER2 overexpression in gastric cancer patients group, to evaluate the relation of HER2 overexpression with prognosis, and to analyze the proportion of herceptin applied to patients in clinical field. Furthermore, the investigators are going to reevaluate the clinical benefit of Herceptin for survival prolongation compared to chemotherapy only.",[44],"Stomach Neoplasms",[46,47],"Genes, erbB-2","Prognosis","UNKNOWN","2014-05-12",{"date":51,"type":40},"2014-05-13",{"date":53,"type":10},"2014-05",{"name":5,"class":6},1]